SIG
CTSO icon

Sargent Investment Group’s Cytosorbents Corp CTSO Stock Holding History

Sargent Investment Group’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$311K Sell
549,900
-62,100
-10% -$42.4K 0.04% 202
2025
Q4 		$391K Sell
612,000
-126,700
-17% -$97.5K 0.05% 184
2025
Q3 		$690K Sell
738,700
-7,500
-1% -$7.39K 0.1% 99
2025
Q2 		$673K Sell
746,200
-77,300
-9% -$77.6K 0.09% 134
2025
Q1 		$824K Sell
823,500
-425,363
-34% -$448K 0.13% 109
2024
Q4 		$1.31M Sell
1,248,863
-377,384
-23% -$370K 0.21% 85
2024
Q3 		$2.44M Buy
1,626,247
+192,747
+13% +$211K 0.44% 48
2024
Q2 		$1.01M Buy
1,433,500
+67,181
+5% +$58.3K 0.21% 81
2024
Q1 		$1.3M Buy
1,366,319
+57,572
+4% +$56K 0.28% 68
2023
Q4 		$1.45M Buy
1,308,747
+51,699
+4% +$76.8K 0.32% 64
2023
Q3 		$2.36M Sell
1,257,048
-32,498
-3% -$93.3K 0.57% 40
2023
Q2 		$4.63M Buy
1,289,546
+71,013
+6% +$225K 1.12% 25
2023
Q1 		$4.22M Buy
1,218,533
+234,400
+24% +$703K 1.11% 23
2022
Q4 		$1.53M Sell
984,133
-124,100
-11% -$184K 0.47% 52
2022
Q3 		$2.03M Buy
1,108,233
+130,737
+13% +$255K 0.63% 41
2022
Q2 		$2.14M Buy
977,496
+150,116
+18% +$345K 0.66% 37
2022
Q1 		$2.64M Buy
827,380
+42,544
+5% +$152K 0.67% 36
2021
Q4 		$3.29M Sell
784,836
-179,305
-19% -$1.01M 0.75% 33
2021
Q3 		$7.83M Buy
964,141
+107,826
+13% +$876K 1.9% 14
2021
Q2 		$6.46M Buy
856,315
+72,145
+9% +$608K 1.53% 18
2021
Q1 		$6.81M Buy
784,170
+110,585
+16% +$1.05M 1.79% 14
2020
Q4 		$5.37M Sell
673,585
-19,153
-3% -$160K 1.7% 15
2020
Q3 		$5.52M Sell
692,738
-7,067
-1% -$63.8K 2.01% 15
2020
Q2 		$6.98M Buy
699,805
+228,050
+48% +$2.09M 2.62% 13
2020
Q1 		$3.65M Buy
471,755
+204,750
+77% +$1.03M 1.68% 19
2019
Q4 		$1.03M Sell
267,005
-28,910
-10% -$126K 0.38% 53
2019
Q3 		$1.49M Sell
295,915
-37,995
-11% -$221K 0.67% 37
2019
Q2 		$2.21M Buy
333,910
+45,840
+16% +$315K 1.01% 23
2019
Q1 		$2.18M Buy
288,070
+38,640
+15% +$301K 1.05% 25
2018
Q4 		$2.02M Buy
+249,430
New +$2.48M 1.24% 22

Other funds holding CTSO

AC
Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SC
Skylands Capital Milwaukee, Wisconsin $814M AUM 32.37% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
CBU
CIBC Bancorp USA Chicago, Illinois $74.4B AUM

Sargent Investment Group's CTSO Position: Q1 2026 in Review

Sargent Investment Group reduced its Cytosorbents Corp (CTSO) stake by 10% in Q1 2026, selling an estimated $42.4K and leaving 549,900 shares worth $311K. The position accounts for 0.04% of the portfolio, ranked #202.

Sargent Investment Group first reported a position in CTSO in Q4 2018 and has held it in 30 quarters since. The position peaked at $7.83M in Q3 2021. 50 funds tracked by Wall St. Rank hold CTSO as of Q1 2026.

  • Sargent Investment Group held 549,900 shares of Cytosorbents Corp worth $311K as of Q1 2026.
  • Sargent Investment Group sold 62,100 Cytosorbents Corp shares in Q1 2026, an estimated $42.4K.
  • Cytosorbents Corp made up 0.04% of Sargent Investment Group's portfolio in Q1 2026, its #202 holding.
  • Sargent Investment Group first reported a position in Cytosorbents Corp in Q4 2018 and has held it in 30 quarters since.
  • Sargent Investment Group's Cytosorbents Corp position peaked at $7.83M in Q3 2021.
  • 50 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2026.

Based on Sargent Investment Group's 13F filing for Q1 2026, filed 11 May 2026.